vs
IMMUCELL CORP（ICCC）与奎斯特诊断（IMDX）财务数据对比。点击上方公司名可切换其他公司
IMMUCELL CORP的季度营收约是奎斯特诊断的4.8倍（$5.5M vs $1.1M）。IMMUCELL CORP净利率更高（-2.5% vs -2015.4%，领先2012.8%）。IMMUCELL CORP同比增速更快（-8.4% vs -23.4%）。IMMUCELL CORP自由现金流更多（$-1.8M vs $-7.0M）。过去两年奎斯特诊断的营收复合增速更高（154.4% vs 3.9%）
ImmuCell Corp是一家总部位于美国的动物健康生物技术企业，主要研发、生产和销售以奶牛为主的家畜相关保健与治疗产品，核心产品包括乳腺炎等常见牛类疾病的防治方案，主要服务北美地区的畜牧养殖户和兽医机构。
奎斯特诊断公司是一家美国临床检验企业，跻身财富500强，业务覆盖美国本土，以及波多黎各、墨西哥、巴西等地区，同时与全球多家医院和诊所保持合作关系，是行业内颇具影响力的医疗诊断服务提供商。
ICCC vs IMDX — 直观对比
营收规模更大
ICCC
是对方的4.8倍
$1.1M
营收增速更快
ICCC
高出14.9%
-23.4%
净利率更高
ICCC
高出2012.8%
-2015.4%
自由现金流更多
ICCC
多$5.2M
$-7.0M
两年增速更快
IMDX
近两年复合增速
3.9%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.5M | $1.1M |
| 净利润 | $-139.7K | $-23.0M |
| 毛利率 | 42.9% | 42.5% |
| 营业利润率 | 0.4% | -2057.5% |
| 净利率 | -2.5% | -2015.4% |
| 营收同比 | -8.4% | -23.4% |
| 净利润同比 | 80.1% | 31.5% |
| 每股收益（稀释后） | $-0.02 | $-0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICCCIMDX
| Q4 25 | — | $1.1M | ||
| Q3 25 | $5.5M | $260.0K | ||
| Q2 25 | $6.4M | $518.0K | ||
| Q1 25 | $8.1M | $2.1M | ||
| Q4 24 | $7.8M | $1.5M | ||
| Q3 24 | $6.0M | $115.0K | ||
| Q2 24 | $5.5M | $104.0K | ||
| Q1 24 | $7.3M | $176.0K |
净利润ICCCIMDX
| Q4 25 | — | $-23.0M | ||
| Q3 25 | $-139.7K | $-10.9M | ||
| Q2 25 | $501.9K | $-9.7M | ||
| Q1 25 | $1.4M | $-6.7M | ||
| Q4 24 | — | $-33.5M | ||
| Q3 24 | $-701.7K | $-13.5M | ||
| Q2 24 | $-1.5M | $-4.5M | ||
| Q1 24 | $-437.9K | $-9.1M |
毛利率ICCCIMDX
| Q4 25 | — | 42.5% | ||
| Q3 25 | 42.9% | 53.5% | ||
| Q2 25 | 43.7% | 67.6% | ||
| Q1 25 | 41.6% | 62.0% | ||
| Q4 24 | 36.5% | 40.0% | ||
| Q3 24 | 26.3% | 43.5% | ||
| Q2 24 | 22.5% | 48.1% | ||
| Q1 24 | 31.6% | 25.6% |
营业利润率ICCCIMDX
| Q4 25 | — | -2057.5% | ||
| Q3 25 | 0.4% | -4249.2% | ||
| Q2 25 | 8.8% | -1900.0% | ||
| Q1 25 | 13.9% | -318.0% | ||
| Q4 24 | 8.0% | -2262.9% | ||
| Q3 24 | -9.6% | -11752.2% | ||
| Q2 24 | -25.3% | -4453.8% | ||
| Q1 24 | -4.1% | -5265.3% |
净利率ICCCIMDX
| Q4 25 | — | -2015.4% | ||
| Q3 25 | -2.5% | -4174.6% | ||
| Q2 25 | 7.8% | -1880.7% | ||
| Q1 25 | 17.9% | -312.0% | ||
| Q4 24 | — | -2255.1% | ||
| Q3 24 | -11.7% | -11733.0% | ||
| Q2 24 | -28.0% | -4355.8% | ||
| Q1 24 | -6.0% | -5186.9% |
每股收益（稀释后）ICCCIMDX
| Q4 25 | — | $-0.75 | ||
| Q3 25 | $-0.02 | $-0.34 | ||
| Q2 25 | $0.06 | $-0.30 | ||
| Q1 25 | $0.16 | $-0.26 | ||
| Q4 24 | $0.09 | $-2.19 | ||
| Q3 24 | $-0.09 | $-0.98 | ||
| Q2 24 | $-0.20 | $-0.36 | ||
| Q1 24 | $-0.06 | $-1.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.9M | $11.6M |
| 总债务越低越好 | $9.5M | — |
| 股东权益账面价值 | $29.8M | $-31.5M |
| 总资产 | $45.7M | $25.8M |
| 负债/权益比越低杠杆越低 | 0.32× | — |
8季度趋势，按日历期对齐
现金及短期投资ICCCIMDX
| Q4 25 | — | $11.6M | ||
| Q3 25 | $3.9M | $18.7M | ||
| Q2 25 | — | $24.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | $3.8M | $8.6M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | $1.3M | $9.3M | ||
| Q1 24 | $960.3K | $5.6M |
总债务ICCCIMDX
| Q4 25 | — | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $8.7M | — | ||
| Q4 24 | $9.0M | — | ||
| Q3 24 | $9.4M | — | ||
| Q2 24 | $9.8M | — | ||
| Q1 24 | $10.2M | — |
股东权益ICCCIMDX
| Q4 25 | — | $-31.5M | ||
| Q3 25 | $29.8M | $-9.2M | ||
| Q2 25 | $29.9M | $1.1M | ||
| Q1 25 | $29.0M | $10.2M | ||
| Q4 24 | $27.5M | $-12.3M | ||
| Q3 24 | $26.4M | $9.7M | ||
| Q2 24 | $23.5M | $22.7M | ||
| Q1 24 | $24.6M | $11.6M |
总资产ICCCIMDX
| Q4 25 | — | $25.8M | ||
| Q3 25 | $45.7M | $43.9M | ||
| Q2 25 | $46.7M | $50.5M | ||
| Q1 25 | $45.6M | $60.4M | ||
| Q4 24 | $45.1M | $35.1M | ||
| Q3 24 | $44.4M | $70.2M | ||
| Q2 24 | $41.9M | $74.7M | ||
| Q1 24 | $43.1M | $71.0M |
负债/权益比ICCCIMDX
| Q4 25 | — | — | ||
| Q3 25 | 0.32× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.33× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.42× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $-5.5M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $-7.0M |
| 自由现金流率自由现金流/营收 | -32.3% | -616.7% |
| 资本支出强度资本支出/营收 | 10.8% | 129.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $715.4K | $-25.4M |
8季度趋势，按日历期对齐
经营现金流ICCCIMDX
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $-1.2M | $-4.5M | ||
| Q2 25 | $1.6M | $-6.3M | ||
| Q1 25 | $1.6M | $-5.9M | ||
| Q4 24 | $-3.1K | $-5.4M | ||
| Q3 24 | $-639.3K | $-5.5M | ||
| Q2 24 | $581.8K | $-6.0M | ||
| Q1 24 | $418.5K | $-3.8M |
自由现金流ICCCIMDX
| Q4 25 | — | $-7.0M | ||
| Q3 25 | $-1.8M | $-5.6M | ||
| Q2 25 | $1.4M | $-6.6M | ||
| Q1 25 | $1.2M | $-6.2M | ||
| Q4 24 | $-199.3K | $-5.6M | ||
| Q3 24 | $-727.7K | $-5.6M | ||
| Q2 24 | $471.0K | $-6.2M | ||
| Q1 24 | $348.1K | $-3.9M |
自由现金流率ICCCIMDX
| Q4 25 | — | -616.7% | ||
| Q3 25 | -32.3% | -2135.4% | ||
| Q2 25 | 22.4% | -1279.5% | ||
| Q1 25 | 15.4% | -288.4% | ||
| Q4 24 | -2.6% | -374.5% | ||
| Q3 24 | -12.1% | -4884.3% | ||
| Q2 24 | 8.6% | -5931.7% | ||
| Q1 24 | 4.8% | -2189.8% |
资本支出强度ICCCIMDX
| Q4 25 | — | 129.9% | ||
| Q3 25 | 10.8% | 403.8% | ||
| Q2 25 | 2.4% | 67.4% | ||
| Q1 25 | 4.1% | 14.4% | ||
| Q4 24 | 2.5% | 14.4% | ||
| Q3 24 | 1.5% | 75.7% | ||
| Q2 24 | 2.0% | 183.7% | ||
| Q1 24 | 1.0% | 13.6% |
现金转化率ICCCIMDX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.19× | — | ||
| Q1 25 | 1.09× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
